Theravance Biopharma, Inc.
TBPH
$8.41
-$0.36-4.11%
| Weiss Ratings | TBPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | TBPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | TBPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.71 | |||
| Price History | TBPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -9.57% | |||
| 30-Day Total Return | -9.72% | |||
| 60-Day Total Return | -9.08% | |||
| 90-Day Total Return | -12.49% | |||
| Year to Date Total Return | -9.38% | |||
| 1-Year Total Return | -7.99% | |||
| 2-Year Total Return | -23.48% | |||
| 3-Year Total Return | -11.47% | |||
| 5-Year Total Return | -63.89% | |||
| 52-Week High % Change | -19.54% | |||
| 52-Week Low % Change | 17.88% | |||
| Price | TBPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $10.90 | |||
| 52-Week Low Price | $7.44 | |||
| 52-Week Low Price (Date) | Aug 09, 2024 | |||
| 52-Week High Price (Date) | Jan 24, 2025 | |||
| Valuation | TBPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 433.86M | |||
| Enterprise Value | 395.33M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.15 | |||
| Earnings Per Share Growth | 19.01% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 6.72 | |||
| Price/Book (Q) | 2.47 | |||
| Enterprise Value/Revenue (TTM) | 6.14 | |||
| Price | $8.41 | |||
| Enterprise Value/EBITDA (TTM) | -9.71 | |||
| Enterprise Value/EBIT | -9.32 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | TBPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 49.31M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | TBPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 650-808-6000 | |||
| Address | 901 Gateway Boulevard South San Francisco, CA 94080 | |||
| Website | www.theravance.com | |||
| Country | United States | |||
| Year Founded | 2013 | |||
| Profitability | TBPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -65.91% | |||
| Profit Margin | -87.63% | |||
| Management Effectiveness | TBPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -7.21% | |||
| Return on Equity | -- | |||
| Income Statement | TBPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 64.38M | |||
| Total Revenue (TTM) | 64.38M | |||
| Revenue Per Share | $1.31 | |||
| Gross Profit (TTM) | 26.74M | |||
| EBITDA (TTM) | -40.73M | |||
| EBIT (TTM) | -42.44M | |||
| Net Income (TTM) | -56.42M | |||
| Net Income Avl. to Common (TTM) | -56.42M | |||
| Total Revenue Growth (Q YOY) | 6.77% | |||
| Earnings Growth (Q YOY) | -82.46% | |||
| EPS Diluted (TTM) | -1.15 | |||
| EPS Diluted Growth (Q YOY) | -82.87% | |||
| Balance Sheet | TBPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 88.35M | |||
| Cash Per Share (Q) | $1.79 | |||
| Total Current Assets (Q) | 161.07M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 175.55M | |||
| Current Ratio (Q) | 5.020 | |||
| Book Value Per Share (Q) | $3.55 | |||
| Total Assets (Q) | 354.16M | |||
| Total Current Liabilities (Q) | 32.09M | |||
| Total Debt (Q) | 49.82M | |||
| Total Liabilities (Q) | 178.62M | |||
| Total Common Equity (Q) | 175.55M | |||
| Cash Flow | TBPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 12.28M | |||
| Cash from Financing (TTM) | -2.50M | |||
| Net Change in Cash (TTM) | -1.75M | |||
| Levered Free Cash Flow (TTM) | -42.00M | |||
| Cash from Operations (TTM) | -11.54M | |||
